Related Experiment Video
Updated: Mar 17, 2026
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
Expression of CD11a (LFA-1) on B-chronic Lymphocytic Leukemia and Lymphoma Cells: Correlation with Cell Surface
R Rabinowitz1, A Polliack2, R Leizerowitz2
1a Hubert H. Humphrey Center for Experimental Medicine and Cancer Research Paul Ehrlich Center for the Study of Normal and Leukemic WBC, The Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Insights
This study found lower CD11a (LFA-1) expression on B-chronic lymphocytic leukemia (CLL) cells compared to non-Hodgkin
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Differentiating B-chronic lymphocytic leukemia (CLL) from B-non-Hodgkin's lymphoma (NHL) in leukemic phase is crucial for accurate diagnosis and treatment.
- CD11a (LFA-1) and surface immunoglobulin (Smig) are cell surface markers that may aid in this differentiation.
- Understanding the expression patterns of these markers in relation to disease characteristics is important.
Purpose of the Study:
- To investigate the expression of CD11a (LFA-1) on CLL and NHL cells.
- To correlate CD11a expression with surface immunoglobulin (Smig) and CD58 (LFA-3) expression.
- To evaluate the utility of CD11a and Smig expression in distinguishing between CLL and NHL.
Main Methods:
- Flow cytometry was used to analyze the expression of CD11a (LFA-1), surface immunoglobulin (Smig), and CD58 (LFA-3) on B-lymphocytes.
- Patients with CLL and NHL in leukemic phase were included in the study.
- Expression levels were correlated with clinical parameters such as white blood cell count and Rai stage.
Main Results:
- CLL cells exhibited a significantly lower proportion of CD11a+ cells and lower Smig intensity compared to NHL cells.
- In CLL, CD11a+ cell proportion inversely correlated with white blood cell count and was lower in advanced Rai stages (2-4).
- A strong correlation was observed between CD11a+ and CD58+ cells in both diseases, but CD11a and Smig intensity correlated only when data from both diseases were pooled.
Conclusions:
- CD11a (LFA-1) expression and Smig intensity are valuable parameters for differentiating between CLL and NHL.
- Lower CD11a expression and Smig intensity are characteristic features of CLL.
- These markers, particularly in combination, can improve diagnostic accuracy in distinguishing these B-cell malignancies.
Abstract:
In the present study the expression of CD11a (LFA-1) was studied on B-chronic lymphocytic leukemia (CLL) cells and B-non-Hodgkin's small lymphocytic lymphoma in leukemic phase (NHL). The expression of CD11a was correlated with that of surface immunoglobulin (Smig) and CD58 (LFA-3). Patients with CLL were found to have a significantly lower proportion of CD11a+ cells than NHL patients, and the intensity of the staining of Smig was lower in CLL when compared with NHL. The proportion of CD11a+ cells in CLL, but not in NHL, was inversely correlated with the total white blood cell count. In CLL patients the percentage of CD11a+ cells was significantly lower in Rai stages 2-4 compared with stages 0-1. There was a strong correlation between the proportion of CD11a+ and CD58+ cells in both CLL and NHL. In contrast, there was no correlation between the proportion of CD11a cells and Smig intensity in both of these diseases when studied separately. However, when the results in these two diseases were pooled, the proportion of CD11a cells correlated with Smig intensity. The present study indicates that Smig intensity and proportion of CD11a+ cells are important criteria for the differential diagnosis between CLL and NHL.
More Related Videos
07:39Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
Published on: January 7, 2019
09:52A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
